Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?

Executive Summary

The recent rebound in the biotechnology sector is "for real," FDA Commissioner McClellan declared during the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23

You may also be interested in...

“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO

The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York

McKesson Splits CEO Into Operations & Strategy: Hammergren & Mahoney

McKessonHBOC is relying on two young McKesson execs acting as a two-person CEO office to drive the integration of distribution and information businesses into a company able to link each episode of care from first patient contact to prescription dispensing.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts